Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06257849
Active, not recruiting Observational

Validity and Reliability of a Danish Version of the Banff Patella Instability Instrument (BPII 2.0-DK)

NCT06257849 · tracked via the Priya Life Science Denmark tracker
Sponsor
Aarhus University Hospital
Phase
Observational
Started
2024-03-01
Last updated
2025-10-01

Condition(s) studied

Patella Dysplasia

Investigational drug(s) / intervention(s)

BPII 2.0

BPII 2.0: Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability

Study summary

The Banff Patella Instability Instrument (BPII 2.0) is a disease-specific quality of life questionnaire designed to assess adults with patellar dislocations.

As the BPII 2.0 already is cross-cultural translate and adapted to Danish the examination of the the psychometric properties of the Danish version is still needed

The aim om this study is to determine validity and reliability of the Danish version BPII 2.0-DK in a Danish populations of patients with patellar dislocation.

Eligibility

Sex
ALL
Min age
14 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Danish Speaking * Patella instability problems Exclusion Criteria: * None

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Aarhus University Hospital Aarhus Denmark
Division of Sports Trauma, Palle Juul-Jensens Boulevard 99 Aarhus N Denmark

More Aarhus University Hospital trials in Denmark

NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer Recruiting
Comprehensive Geriatric Assessment for Perioperative Optimization in Cystectomy Recruiting
Body Project SMIL: Prevention of Eating Disorders Among Young Women With Psychiatric Illness With the Body Project Starting soon
Clinical Prediction of Post-surgical Pain Recruiting
The Lung Microbiome and Endobronchial Valve Treatment Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06257849 on ClinicalTrials.gov ↗ ← All trials in Denmark